Trials / Withdrawn
WithdrawnNCT00583258
A Randomized Study of Whether Alfuzosin(Xatral) Helps in the Passage of Kidney Stones
A Randomized, Double-Blinded Placebo-Controlled Trial of Alfuzosin (Xatral)in the Management of Distal Ureteral Calculi
- Status
- Withdrawn
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Unity Health Toronto · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Patients who present for the first time to Emergency Room with renal colic due to a distal ureteral calculus (as diagnosed with spiral CT scan and KUB) will be randomized to receive Xatral 10mg po once a day or placebo once discharged from the ER. The purpose of this study is to assess if patients treated with Xatral will have a higher spontaneous passage rate of their ureteral stone than those treated with placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alfuzosin (Xatral) | 10 mg PO once a day |
| DRUG | Placebo Alfuzosin | 10 mg PO once a day |
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2009-09-01
- Completion
- 2009-10-01
- First posted
- 2007-12-31
- Last updated
- 2015-07-31
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT00583258. Inclusion in this directory is not an endorsement.